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1. Summary
We recently reported a new method to purify the induced pluripotent stem (iPS)-
derived osteoprogenitors (iPSop). In this paper, we optimized the procedure and
characterized cells at each process step. We observed that 10 days of treatment
with FGF-2, IGF-1 and TGF-b (FIT) resulted in early-phase osteoblasts and
14 days of treatment resulted in late-phase osteoblasts. We found that treatment
with 1,25(OH)2 vitamin D3 increased expression of osteocalcin and decreased
expression of tissue-non-specific alkaline phosphatase and runt-related transcrip-
tion factor 2 (RUNX2) in iPSop-day14 cells (cells treated with FIT for 14 days).
Therefore, iPSop-day14 cells were promoted to mature osteoblasts by 1,25(OH)2
vitamin D3 treatment. In addition, we found that 1,25(OH)2 vitamin D3 treatment
for 14 days enhanced not only mineralization but also expression of osteocyte
markers, including dentin matrix protein-1 and fibroblast growth factor-23, in
iPSop cells. Therefore, 1,25(OH)2 vitamin D3 is a potent promoter of osteo-
blast–osteocyte transition. The results of this study suggest that it is possible
to evaluate both early- and late-phase osteoblasts and to apply cells to drug
screening for anabolic drugs that stimulate bone formation.
2. Introduction
Induced pluripotent stem cells (iPSCs) can generate a variety of patient-specific
cells and are used to explore disease mechanisms and novel therapeutic molecular
targets in drug development [1–4]. Recent studies have reported on a number of
different types of cells generated from iPSCs [5–7]. We have previously developed
an effective procedure to generate not only osteoblastic cells but also osteocyte-like
cells [8,9]. Osteocytes, once considered as silent cells trapped in mineralized bone,
are now identified as key regulators of bone remodelling [10,11]. Osteocytes are
postmitotic, terminally differentiated osteoblasts and many reside in mineralized
matrices. The most abundant cell in bone and central to bone remodelling, osteo-
cytes secrete many soluble factors that not only target cells on the bone surface but
also target other organs. Osteocytes most abundantly express receptor activator of
nuclear factor kappa-B ligand, which functions as a key factor in osteoclast differ-
entiation and activation. Therefore, any drugs targeting osteocyte function and
signalling pathways will have a major impact on the bone remodelling process.
Currently, much research into drug development, particularly for osteoporosis,
is focused on targeting osteocytes. For this reason, the generation of osteocytes
has become particularly important.
Osteoporosis is a very common health problem among elderly people and is
thought to affect more than 200 million people worldwide [12]. With ageing popu-
lations in many countries, the incidence of osteoporosis will increase further.
Therefore, it is important to develop novel drugs for the treatment of osteoporosis
[13–15]. Osteoporosis is caused by an uncoupling of bone resorption from bone
& 2015 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
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formation and is associated with reductions in bone strength
determined by bone mineral density and bone quality.
Reductions in bone strength occur because of an imbalance
between the activity of osteoclasts and osteoblasts. In addi-
tion, bone formation is impaired in elderly people [16–18],
and loss of bone mineral density is caused by a decrease
in calcium absorption with ageing [19]. Consequently, the
microarchitecture of trabecular bone deteriorates [20].
Osteoporosis drugs are categorized into two classes: antire-
sorptive drugs that inhibit bone resorption and anabolic drugs
that stimulate bone formation. The bisphosphonates (BPs) are
antiresorptive drugs and are most commonly prescribed for
the treatment of osteoporosis [15,16,21,22]. However, BPs may
cause bisphosphonate-related osteonecrosis of the jaw, which
is a rare but well recognized serious side effect of long-term
bisphosphonate use [23–27]. Therefore, there is a need for ana-
bolic drugs that could effectively modulate osteoblast or
osteocyte activity to regenerate bone. iPSC technology can be
applied to drug assessment and to patient-specific approaches
to examine individual differences in pharmacokinetic and
pharmacodynamic features.
All therapeutic management strategies for the prevention
and treatment of osteoporosis include recommendations for
calcium and vitamin D supplementation [28]. The active
form of vitamin D, 1,25(OH)2 vitamin D3, contributes to a
wide range of biological activities by binding to the nuclear
vitamin D receptor. It is well established that the appropriate
use of vitamin D can prevent the progression of osteoporosis.
Many studies have shown that vitamin D has both anabolic
and catabolic roles in bone homeostasis. However, the effects
of vitamin D on bone tissue and bone cells have not yet been
entirely evaluated. It is important to assess the precise effects
of vitamin D on the osteolineage cells, osteoblasts and osteo-
cytes. Here, we show that human osteolineage cells derived
from human iPSCs (hiPSCs) can provide an ideal model to ana-
lyse the effects of 1,25(OH)2 vitamin D3 [9,29–33]. Our results
suggest that these osteolineage cells could be used for high-
throughput screening technologies to develop new drugs to
treat osteoporosis. In a recent advance in drug discovery for
osteoporosis using treatment targeting sclerostin, it is indicated
that the osteocyte must be one of the major targets [29].
In this study, we treated tissue-non-specific alkaline
phosphatase (TNAP) positive osteolineage cells derived from
hiPSCs, referred to as iPS-derived osteoprogenitors (iPSop),
with 1,25(OH)2 vitamin D3. We compared iPSop cells with
TNAP positive osteolineage cells derived from human
mesenchymal stem cells (hMSCs), referred to as MSC-derived
osteoprogenitors (MSCop). We found that osteocalcin (OCN), a
late-phase marker for osteoblasts, was increased, and several
osteocyte markers were detectable in iPSop cells but not in
MSCop cells, after 1,25(OH)2 vitamin D3 treatment. Therefore,
we suggest that iPSop cells can respond to osteogenic agents
and may be a useful tool for drug assessment. Furthermore,
this model could be used to develop new agents to promote
osteogenic progression.
3. Material and methods
3.1. Cell culture and reagents
Human iPSCs (line 201B7; Riken Cell Bank, Tsukuba, Japan)
were maintained with SNL76/7 feeder cells, clonally derived
from a mouse fibroblast STO cell line transformed with neomy-
cin resistance genes and murine LIF genes, in human ES
medium (Dulbecco’s modified Eagle’s medium, nutrient mix-
ture F-12 (DMEM/F-12, Invitrogen, Carlsbad, CA) with 20%
knockout serum replacement (Invitrogen) supplemented with
1 non-essential amino acids solution (Chemicon, Temecula,
CA), 2 mM L-glutamine (Chemicon), 1 mM 2-mercaptoethanol
(Wako Pure Chemical Industries Ltd., Osaka, Japan), 1%
penicillin/streptomycin (Invitrogen) and 5 ng ml21 human
fibroblast growth factor (FGF)-2 (ReproCELL Incorporated,
Yokohama, Japan)). hMSCs were purchased Lonza (Basel,
Switzerland), cultured in BulletKit MSC growth medium
(Lonza) and used at passage 3 to 5. The 1,25(OH)2 vitamin D3
was purchased from Kyowa Hakko Kirin Co., Ltd. (Tokyo,
Japan). Insulin-like growth factor (IGF)-1 and transforming
growth factor (TGF)-b were purchased from Wako Pure
Chemical Industries Ltd.
3.2. Embryoid body formation and in vitro osteogenic
differentiation
The hiPSC colonies were dissociated with a cell scraper
and transferred to low attachment Petri dishes to generate
embryoid bodies (EBs). EBs were maintained in suspension in
human ES medium without FGF-2 for 6 days. On day 6, the
EBs were treated with 2 mM thiazovivin (Wako Pure Chemical
Industries Ltd.) in human ES medium without FGF-2 for 1 h at
378C and collected and dissociated in 0.5 mg ml21 collagenase
type IV (Wako Pure Chemical Industries Ltd.) for 20 min at
378C, followed by treatment with 0.05% trypsin–EDTA (Invi-
trogen) for 5 min at 378C. Cell suspensions were rinsed with
a-MEM (Invitrogen, Carlsbad, CA) with 10% FBS, and cells
were seeded onto cell culture dishes and cultured in osteoblast
medium (OBM; a-MEM with 10% FBS, 50 mg ml21 L-ascorbic
acid (Wako Pure Chemical Industries Ltd.), 10 mM b-glycero-
phosphate (Wako Pure Chemical Industries Ltd.) and 10 nM
dexamethasone (Wako Pure Chemical Industries Ltd.)). FGF-
2, IGF-1 and TGF-b (FIT) were added on the following day
(day 0) at a final concentration of 25 ng ml21 FGF-2,
100 ng ml21 IGF-1 and 1 ng ml21 TGF-b. After culture in
OBM with FIT for 0 (iPSop-day0), 4 (iPSop-day4), 10 (iPSop-
day10) or 14 days (iPSop-day14), the cells were analysed and
isolated by flow cytometry. In addition, the hMSCs were cul-
tured in OBM with FIT and then isolated by flow cytometry
on day 4 (MSCop-day4) or day 14 (MSCop-day14).
3.3. Flow cytometrical analysis and cell sorting
After washing with phosphate-buffered saline (PBS), the
cells were treated with 0.05% trypsin–EDTA for 10 min at
378C. The trypsinized cells were stained with phycoerythrin-
conjugated anti-human alkaline phosphatase (ALP) antibody
(R&D Systems, Minneapolis, MN) at a concentration of
10 ml/2  105 cells for 45 min on ice. After staining, cells
were washed three times with PBS, suspended in PBS contain-
ing 0.5% FBS, passed through a 40-mm mesh filter and
maintained at 48C until FACS sorting. We defined TNAP posi-
tive cells from hiPSCs and hMSCs as iPSop and MSCop,
respectively. Dead cells were excluded by propidium iodide
staining (2 mg ml21) and forward scatter. Flow cytometrical
analysis and cell sorting were performed on a FACS Aria
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3.4. Induction of osteoblast differentiation in
osteoprogenitor-derived hiPSCs and hMSCs with
1,25(OH)2 vitamin D3
After culture in OBM with FIT for 14 days (iPSop-day14), the
cells were isolated by flow cytometry, and 1,25(OH)2 vitamin
D3 at a concentration of 10 or 50 nM was added on the follow-
ing day (day 0). The medium was refreshed every 3 days, and
the cells were analysed on day 6 and day 12. In addition, after
culture in OBM with FIT for 4 days (iPSop-day4, MSCop-day4)
or 14 days (iPSop-day14, MSCop-day14), iPSop and MSCop
cells were isolated by flow cytometry and were treated with
50 nM 1,25(OH)2 vitamin D3. The medium was refreshed
every 3 days, and the cells were analysed on day 6 and day 12.
3.5. mRNA expression
Total RNA was extracted using QIAzol reagent (Qiagen Inc.,
Valencia, CA) according to the manufacturer’s instructions.
cDNA was synthesized using a high-capacity cDNA reverse
transcription kit (Applied Biosystems, Foster City, CA).
Real-time RT-PCR (qRT-PCR) was performed using Premix
Ex Taq reagent (Takara Bio Inc., Shiga, Japan) according
to the manufacturer’s instructions. Target genes included
type I collagen (COL1A1), TNAP, runt-related transcription
factor 2 (RUNX2), OCN and osterix (OSX). 18S rRNA was
used as an internal control. All primers and probes are pre-
sented in table 1. Relative expression of genes of interest
was estimated using the DDCt method.
RT-PCR was performed to examine some of the osteo-
cyte-specific markers using ExTaq DNA polymerase
(Takara Biotechnology, Shiga, Japan). Target genes included
dentin matrix protein-1 (DMP-1), fibroblast growth factor-23
(FGF-23), matrix extracellular phosphoglycoprotein (MEPE)
and podoplanin (PDPN). b-Actin was used as an internal
control. Amplified PCR products were electrophoresed on
2% agarose gels. PCR primers used are listed in table 2.
3.6. Mineralization
The iPSop-day14 cells were treated with 1,25(OH)2 vitamin D3
for 2 weeks. The medium was removed, and the cells were
rinsed in PBS and fixed in 4% paraformaldehyde for 5 min at
room temperature. For mineralization, plates were treated
with alizarin red solution for 5 min at room temperature.
After 5 min, plates were rinsed in PBS and visually examined.
3.7. Statistical analysis
All data are expressed as the mean+ standard deviation
(s.d.). When ANOVA indicated differences among the
groups, multiple comparisons between each experimental
group were performed using the Bonferroni test. Statistical
significance was defined as p , 0.05.
4. Results
4.1. Induction of iPSop cells
As expected, the hiPSCs expressed a large amount of TNAP.
We found that cells separated from EBs rapidly lost
TNAP expression, but FIT treatment greatly increased TNAP
expression (figure 1a,b). We isolated TNAP positive cells by
FACS sorting and defined them as iPSop cells. Furthermore,
we estimated osteoblast-specific markers in iPSop cells at each
differentiation stage during culture in OBM. COL1A1 and
TNAP expression increased over time. In iPSop-day10 cells,
the expression of TNAP and RUNX2 was two times that in
Table 1. Primers used for qRT-PCR.
gene symbol GenBank accession no. forward primer sequence reverse primer sequence
COL1A1 NM_000088.3 50-gggattccctggacctaaag-30 50-ggaaacctcgctctcca-30
TNAP NM_000478.3 50-caaccctggggaggagac-30 50-gcattggtgttgtacgtcttg-30
RUNX2 NM_001024630.2 50-gtgcctaggcgcatttca-30 50-gctcttcttactgagagtggaagg-30
OCN NM_007541.2 50-agactccggcgctacctt-30 50-ctcgtcacaagcagggttaag-30
OSX NM_152860.1 50-catctgcctggctccttg-30 50-caggggactggagccata-30
18SrRNA M11188.1 50-cggacaggattgacagattg-30 50-cgctccaccaactaagaacg-30
Table 2. Primers used for RT-PCR.
gene symbol GenBank accession no. forward primer sequence reverse primer sequence
DMP-1 NM_001079911 50-caggagcacaggaaaaggag-30 50-ctggtggtatcttgggcact-30
FGF-23 NM_020638.2 50-tatttcgacccggagaactg-30 50-ggtatgggggtgttgaagtg-30
PHEX NM_000444.5 50-aagaggaccctgggagaaaa-30 50-gggactgtgagcaccaattt-30
MEPE NM_001184694 50-ccctttctgaagccagtgag-30 50-ttttcttcccccaggagttt-30
PDPN NM_001006624 50-ccagcgaagaccgctataag-30 50-acgatgattgcaccaatgaa-30
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iPSop-day0 cells, but OSX expression was not detected. In iPSop-
day14 cells, TNAP expression was further increased, RUNX2
expression was decreased and OSX expression sharply
increased. Therefore, culture in OBM led to the differentiation
of iPSop cells into osteoblasts over time (figure 1c). These results
demonstrated that we could obtain osteoblasts at various stages
of differentiation from iPSCs.
4.2. 1,25(OH)2 vitamin D3 promotes osteogenic
differentiation of iPSop cells
The treatment of iPSop-day14 cells with 1,25(OH)2 vitamin
D3 for 6 days increased the expression of COL1A1 and
OCN and decreased the expression of TNAP and RUNX2
(figure 2a). The increases or decreases in osteoblast markers
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Figure 1. The expression of TNAP during hiPSC-to-osteogenic cell differentiation and the expression of osteoblast markers. (a) The frequency of TNAP positive cells in
hiPSCs, EBs and single cells derived from EBs cultured in OBM with FGF-2/IGF-1/TGF-b (FIT). (b) Flow cytometrical analysis was performed on hiPSCs, EBs and single
cells cultured in OBM with FIT for 0, 4, 10 and 14 days. (c) qRT-PCR analysis of COL1A1, TNAP, OSX and RUNX2 was performed on iPSop-day0, 4, 10 and 14 cells.
mRNA levels were normalized to those of 18S rRNA. Experiments were performed in triplicate. Values represent the mean+ s.d., n¼ 3. Bonferroni correction for
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occurred in a dose-dependent manner, and the longer the
treatment, the more significant the change in osteoblast
marker expression (figure 2b).
4.3. iPSop cells are more reactive to 1,25(OH)2 vitamin
D3 than MSCop cells
Furthermore, we investigated the difference in response to
1,25(OH)2 vitamin D3 between iPSop cells and MSCop cells.
We treated iPSop-day4 and MSCop-day4 cells, which were iso-
lated by flow cytometryafter culture in OBM with FIT for 4 days,
with 1,25(OH)2 vitamin D3. Every osteoblast marker in MSCop-
day4 cells increased but there was little difference between 6 and
12 days of 1,25(OH)2 vitamin D3 treatment (figure 3a). In iPSop-
day4 cells, again every osteoblast marker increased with
1,25(OH)2 vitamin D3 treatment and marker expression contin-
ued to increase over time (figure 3a). In iPSop-day14 cells,
expression of COL1A1 and OCN increased and expression of
TNAP, RUNX2 and OSX decreased over time with 1,25(OH)2
vitamin D3 treatment (figure 3b). However, TNAP and
RUNX2 expression in MSCop-day14 cells did not decrease
with 1,25(OH)2 vitamin D3 treatment (figure 3b). These results
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Figure 2. Expression of osteoblast markers after 1,25(OH)2 vitamin D3 treatment. (a) After isolation by flow cytometry, iPSop-day14 cells were treated with vehicle
(control), 10 nM or 50 nM 1,25(OH)2 vitamin D3 for 6 days or (b) 12 days. Expression of COL1A1, TNAP, OCN and RUNX2 was analysed with qRT-PCR, and mRNA
levels were normalized to those of 18S rRNA. Experiments were performed in triplicate. Values represent the mean+ s.d., n¼ 4. Bonferroni correction for multiple
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D3 treatment than MSCop cells, and iPSop-day14 cells were
advancing to a late phase of osteoblast differentiation.
4.4. iPSop cells expressed various osteocyte marker
genes with 1,25(OH)2 vitamin D3 treatment
Osteocyte-specific markers, such as DMP-1, FGF-23 and MEPE,
were detected in iPSop-day14 cells treated with 1,25(OH)2 vita-
min D3 for 14 days (figure 4a). In addition, 1,25(OH)2 vitamin
D3 promoted mineralization in iPSop-day14 cells, when com-
pared with vehicle alone (figure 4b). Therefore, these cells had
proceeded to an early phase of osteocyte differentiation.
5. Discussion
Osteoporosis is a very common disease normally associated
with ageing and caused by bone resorption overtaking bone for-
mation. Dietary or supplemental calcium and activated vitamin
D are required to reduce the risk of osteoporosis [15]. In clinical
use, the intestinal calcium absorption effect of the prodrug alfa-
calcidol (1-hydroxyvitamin D3) becomes active at a daily dosage
of 1.0 mg and then suppresses parathyroid hormone and inhibits
bone resorption in adults. However, vitamin D has a narrow
therapeutic window and bone resorption can occur at higher
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Figure 3. Expression of osteoblast markers in iPSop and MSCop cells at different differentiation stages after 1,25(OH)2 vitamin D3 treatment. iPSop and MSCop cells
express various osteoblast markers. Comparison of expression of osteoblast marker genes between cells treated with vehicle and 1,25(OH)2 vitamin D3. (a) In iPSop-
and MSCop-day4 cells. (b) In iPSop- and MSCop-day14 cells. These cells were treated with vehicle (white bar) or 50 nM 1,25(OH)2 vitamin D3 (black bar) for 6 or
12 days. Expressions of COL1A1, TNAP, OCN, RUNX2 and OSX were analysed with qRT-PCR, and mRNA levels were normalized to those of 18S rRNA. Experiments were
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catabolic effects on osteolineage cells. Although the mechanism
underlying this biphasic effect is clinically important, to date, it
is not well understood. The study of osteoremodelling by
1,25(OH)2 vitamin D3 has been limited by difficulty in obtaining
osteocytes, which have a central role in that process.
We recently reported a new method to purify osteoprogeni-
tors from hiPSCs. One of the unique advantages of our method
is the ability to generate osteocyte-like cells. In this study, we
used our system to evaluate the effects of 1,25(OH)2 vitamin
D3 on osteoblast differentiation. First, we identified the optimal
timing to obtain iPSop cells by sorting TNAP positive cells at
different time points. Osteoblast marker gene expression dif-
fered over time. Cells liberated from hiPSC-derived EBs after
10 days of culture in OBM with FIT were sorted as TNAP
positive cells and these cells showed increased expression of
RUNX2. Four days later, after 14 days of culture in OBM with
FIT, OSX expression was significantly increased (figure 1c).
Therefore, it appears that cells liberated from hiPSC-derived
EBs after 14 days of culture in OBM with FIT are differentia-
ted into late-phase osteoblasts [34]. Next, we investigated
the effects of 1,25(OH)2 vitamin D3 on these iPSop cells.
We found that iPSop cells responded to 1,25(OH)2 vitamin
D3 and the expression of osteoblast markers in these cells
was affected in a dose-dependent manner. The effects of
1,25(OH)2 vitamin D3 on osteoblast marker gene expression
suggested that iPSop-day4 cells were early-phase osteoblasts
and iPSop-day14 cells were late-phase osteoblasts. Treatment
with 1,25(OH)2 vitamin D3 increased all osteoblast markers in
iPSop-day4 cells and MSCop-day4 cells. However, 1,25(OH)2
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osteoblast markers (TNAP, RUNX2 and OSX) and increased
OCN expression in iPSop-day14 cells but not in MSCop-
day14 cells. Moreover, we observed an increase of mineraliz-
ation in iPSop-day14 cells after 14 days of 1,25(OH)2 vitamin
D3 treatment. We previously showed that it took 40 days for
iPSop cells to express osteocyte markers [9]. The current obser-
vations clearly showed that 1,25(OH)2 vitamin D3 could be a
potent accelerator of osteodifferentiation, particularly from
late- to early-phase osteocytes. However, we did not detect an
increase in sclerostin (an osteocyte-derived inhibitor of cultured
osteoblasts) expression in this study. We suggest that high dose
1,25(OH)2 vitamin D3 treatment could induce sclerostin
expression in newly formed osteocytes or existing osteocytes,
which, in turn, could cause inhibition of Wnt signalling and
accelerate the resorption of bone tissue.
Another important point is that this method could be
used for research into new drugs for osteoporosis. Human-
cell-based in vitro assay systems are a basic requisite for
drug discovery and iPSCs reprogrammed from somatic cells
can provide an opportunity to establish these systems [3,4].
Recent research has revealed that osteocytes are part of the
command centre for osteoremodelling, and one reason is
that sclerostin is exclusively secreted from osteocytes [35]. A
neutralizing antibody to sclerostin has been shown to be
effective in initial preclinical and early clinical trials. Postme-
nopausal women treated with a neutralizing antibody to
sclerostin showed an increase in markers of bone formation
[29]. Therefore, agents regulating osteocyte functions such
as sclerostin secretion could be effective in the treatment of
osteoporosis. However, screening methods using animal
models may not reflect the human situation and some com-
pounds found to be successful in cellular or animal models
have failed to show effectiveness in clinical trials [35,36].
It has been postulated that drug screening using iPSCs
could identify compounds that increase differentiation and
promote maturation in target cells [36]. To date, there are
few examples of the use of high-throughput screening
methods to assess differentiation. We believe that the iPSop
cells generated using our method could be a valuable cell
source for high-throughput screening to research new drugs
for a range of diseases, including osteoporosis.
6. Conclusion
Treatment with 1,25(OH)2 vitamin D3 could promote osteo-
genic differentiation in iPSop cells and could accelerate the
expression of osteocyte marker genes. This is the first report
showing that 1,25(OH)2 vitamin D3 can promote osteocyte
generation. Because iPSCs expand into a large number of
cells, this method could be used for high-throughput screen-
ing of new drugs to treat osteoporosis. We hope that our
method will provide us a new platform for research into
the treatment of osteoporosis and other bone diseases.
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